Clinical trials sponsored by Peking University People's Hospital

Phase breakdown

Conditions studied

Recruiting trials led by Peking University People's Hospital

• A Cohort Study of Combined Cryoablation and Thermal Ablation for Non-surgical Treatment of Breast Cancer Patients
  NCT07238894 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: Female · 1 location
• A RWS of SC MTX in Chinese RA Patients
  NCT07463937 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Ablation Compare With Surgery for Early Breast Cancer
  NCT07484087 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years and older · Sex: Female · 1 location
• Automated Bone Age Estimation From Noncontrast Abdominal CT Using Deep Learning
  NCT07162168 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
  NCT06794008 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients
  NCT07632664 · Phase: Not applicable (e.g. observational or device study) · Ages: 65 Years and older · Sex: All (male and female) · 1 location
• De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
  NCT06692725 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Evaluation of Musculoskeletal Aging and Related Disorders Via Advanced Clinical Imaging
  NCT07474571 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• FAP-targeted PET/NIR in Lung Malignant Tumors
  NCT07498933 · Phase: Not specified · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study
  NCT05576389 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Fucoidan in the Treatment of Active Rheumatoid Arthritis
  NCT07045896 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE)
  NCT07617740 · Phase: Early Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B
  NCT07328711 · Phase: Early Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Kahook Dual Blade Goniotomy in Chronic Primary Angle-Closure Glaucoma
  NCT07517302 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · 1 location
• Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
  NCT06930807 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Long-Term Outcomes in SLE at Peking University People's Hospital
  NCT07005479 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
  NCT07359040 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Multiomics Tumor Evolution Model of NSCLC
  NCT05352035 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients
  NCT04750122 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
  NCT07586813 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
  NCT07586826 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Beijing Angle Closure Progression Study
  NCT05563623 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · 1 location
• To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
  NCT07291921 · Phase: Not specified · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Vitreous Zonule in Primary Angle-Closure Glaucoma
  NCT07523139 · Phase: Not specified · Ages: 30 Years to 79 Years · Sex: All (male and female) · 1 location
• ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
  NCT06970912 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location

Common questions

How many trials is Peking University People's Hospital recruiting for?

Peking University People's Hospital is the lead sponsor of 25 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.